STOCK TITAN

UL Solutions Collaborates on Cross-Industry Initiative to Modernize Life Science Regulated Training

The proposed guidance remains an industry submission for FDA consideration, not an adopted regulatory change.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
partnership
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UL Solutions research helped shape an industry proposal to strengthen how life sciences organizations prepare employees for critical tasks.

  • UL Solutions contributed ULTRUS® ComplianceWire® subject matter expertise to a cross-industry proposal submitted to the U.S. Food and Drug Administration for consideration.
  • The research covered more than 470 million completed learning activities across 594 companies, providing a broad view of opportunities to strengthen training in regulated organizations.
  • The proposal recommends further aligning training and assessment with the knowledge and practical skills employees need for their roles.

NORTHBROOK, Ill.--(BUSINESS WIRE)-- UL Solutions (NYSE: ULS), a global leader in applied safety science, today announced its collaboration on a cross-industry proposal to the U.S. Food and Drug Administration (FDA) that recommends modernizing how life sciences organizations train and qualify personnel performing regulated work.

UL Solutions announced its collaboration on a cross-industry proposal to the U.S. Food and Drug Administration (FDA) that recommends modernizing how life sciences organizations train and qualify personnel performing regulated work.

UL Solutions announced its collaboration on a cross-industry proposal to the U.S. Food and Drug Administration (FDA) that recommends modernizing how life sciences organizations train and qualify personnel performing regulated work.

The Association for GxP Excellence submitted the proposed “Guidance for Industry: Modernizing GxP Quality Training Programs through Competency-Based Learning Models” to the FDA for consideration. UL Solutions worked with other industry participants to develop the proposal. The FDA has not adopted or endorsed the proposal.

Life sciences employees perform work that can affect product quality and patient safety, so companies must train them and document that training in preparation for regulatory audits. Reading and acknowledging standard operating procedures, or SOPs, remains an important part of many programs. The proposal identifies an opportunity to complement that foundation with instruction and assessment that provides a more modern approach to how training is delivered. Depending on each employee’s role, tasks and required skills, those methods may include instructor-led learning, simulations, hands-on practice and e-learning.

“Successful training helps life sciences employees perform critical work consistently, supporting the quality and safety of products that patients rely on,” said John Genovesi, executive vice president and president of Risk and Compliance Software at UL Solutions. “This new proposal offers a modernized approach that can help life sciences organizations better prepare employees to perform critical work consistently while supporting product quality and patient safety.”

UL Solutions contributed findings from aggregate ComplianceWire® research on training practices across regulated companies. ComplianceWire®, a learning and qualification management system designed for regulated industries such as pharmaceuticals, biotechnology, medical devices, healthcare and biologics, helps organizations manage employee training, qualifications, compliance records and audit readiness.

The research reviewed 470,139,690 completed learning activities at 594 companies from 1998 through 2022. It found that 75% involved controlled documents and SOPs, while only 18% of those SOPs were followed by an assessment of understanding. In a separate analysis of 10,119,645 completed procedures, 54% were recorded as read and understood in less than two minutes. These findings do not determine whether any individual employee was adequately trained or qualified. Instead, they highlight an opportunity for organizations to supplement training and assessments with new modalities that can directly demonstrate understanding and the ability to perform critical work.

The proposal recommends setting a clear learning goal for each procedure, then choosing training and assessment methods that fit the goal. A short quiz may show whether an employee remembers key information, while an observed task may better show whether an employee can operate equipment or complete a complex process.

A committee of the Association for GxP Excellence developed the proposal with participants connected to pharmaceutical and biotechnology companies, academic institutions, professional associations, consulting organizations and UL Solutions.

The proposed guidance and its cover letter are available through the FDA public docket FDA-2026-D-10066. The document is an industry-submitted proposal for FDA consideration and does not change applicable laws or regulations.

Learn more about ULTRUS® ComplianceWire® learning and qualification management software by UL Solutions at https://www.ul.com/software/ultrus/compliancewire-lms.

About UL Solutions

A global leader in applied safety science, UL Solutions Inc. (NYSE: ULS) transforms safety, security and sustainability challenges into opportunities for customers in more than 110 countries. UL Solutions delivers testing, inspection and certification services, advisory offerings and software solutions that support our customers’ product innovation and business growth. The UL Mark serves as a recognized symbol of trust in our customers’ products and reflects an unwavering commitment to advancing our safety mission. We help our customers innovate, launch new products and services, navigate global markets and complex supply chains, and grow sustainably and responsibly into the future. Our science is your advantage.

Media contacts:
Tyler Khan
UL Solutions
ULNews@UL.com
T: +1 (847) 664.2139

Steven Brewster
UL Solutions
ULNews@UL.com
T: +1 (847) 664.8425

Source: UL Solutions

Key Terms

gxp regulatory
gxp (often written GxP) is an umbrella term for a family of quality guidelines and regulatory standards—such as Good Manufacturing Practice (GMP), Good Clinical Practice (GCP) and Good Laboratory Practice (GLP)—used in regulated industries to ensure products, processes and data are consistently produced, controlled and documented to meet safety, quality and integrity requirements. It works by prescribing principles and operational controls (written procedures, record-keeping, personnel training, equipment qualification, validation, traceability and regular internal and external audits or inspections) rather than a single rule; specific obligations depend on the particular GxP standard and the regulator that enforces it. GxP compliance ensures processes and records meet regulatory expectations but is not a standalone proof of product effectiveness or commercial success.
standard operating procedures technical
Standard operating procedures (SOPs) are written step-by-step instructions that describe how an organization performs routine tasks to ensure work is done consistently, safely, and in compliance with rules. For investors, strong SOPs reduce the chance of costly errors, regulatory fines, or production delays—think of them as a recipe that helps a company deliver the same expected outcome each time, which supports predictable performance and risk management.

Keep reading